An intensive 1-day meeting that delves into the latest in oligonucleotides chemistry, process & analytical development, therapeutics, antisense therapy & a meeting place for experts working within cutting-edge oligo research & therapeutic development.
Our Symposiums are delivered through Swapcard, our market-leading and highly interactive digital event platform. Alongside the live programme, it has a variety of other features to maximise your event experience, including AI-assisted match-making with other delegates, additional resource such as white papers, exhibitor pages allowing you to connect with leading solution providers and a host of On-Demand content.
Our LinkedIn group aims to foster discussion and collaboration between experts working in proteins, bispecifics, peptides and oligonucleotides
Attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions working within Oligonucleotides
Track 1 – Oligo Chemistry, Formulation & Delivery AI/Machine Learning
Track 2 – Oligo Therapeutics
The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future
Below were some of the key speakers of our Virtual Symposium: Oligonucleotides: Chemistry & Therapeutics 2021 Event
Wave Life Sciences
Networking and knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences.
ABL Inc, is a leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations – including industry, government, and academic entities – to support their quest in improving public health. ABL Inc. –a subsidiary of the French bioindustrial group Institut Mérieux, which fights against infectious diseases and cancers, through the complementary approaches of its companies in the fields of diagnosis, immunotherapy, food safety and nutrition –maintains global GMP facilities meeting U.S. and European regulatory standards, providing cGMP biomanufacture of virus-based oncolytic therapies, gene therapies, vaccines, and protein-based immunotherapeutic products. ABL’s CDMO services include bulk drug substance, live virus fill/finish of drug product, process and assay development, and bioanalytical testing.
As a CRO, ABL’s immunologists use an integrated array of optimized immunology and molecular laboratory assay platforms, to extract immunological correlates of activity and response in both preclinical studies and clinical trials. To stay informed on the latest updates, please follow us on LinkedIn, Twitter and Facebook and subscribe to our mailing list.